These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28679508)

  • 1. A Scale of Agonism and Allosteric Modulation for Assessment of Selectivity, Bias, and Receptor Mutation.
    Kenakin T
    Mol Pharmacol; 2017 Oct; 92(4):414-424. PubMed ID: 28679508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Operational Models of Agonism and Allosterism at Receptors with Multiple Orthosteric Binding Sites.
    Gregory KJ; Giraldo J; Diao J; Christopoulos A; Leach K
    Mol Pharmacol; 2020 Jan; 97(1):35-45. PubMed ID: 31704718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The operational model of allosteric modulation of pharmacological agonism.
    Jakubík J; Randáková A; Chetverikov N; El-Fakahany EE; Doležal V
    Sci Rep; 2020 Sep; 10(1):14421. PubMed ID: 32879329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
    O'Brien JA; Lemaire W; Chen TB; Chang RS; Jacobson MA; Ha SN; Lindsley CW; Schaffhauser HJ; Sur C; Pettibone DJ; Conn PJ; Williams DL
    Mol Pharmacol; 2003 Sep; 64(3):731-40. PubMed ID: 12920211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for positive allosteric modulators: assessment of modulator concentration-response curves as a screening paradigm.
    Langmead CJ
    J Biomol Screen; 2007 Aug; 12(5):668-76. PubMed ID: 17478477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties.
    Urwyler S; Gjoni T; Koljatić J; Dupuis DS
    Neuropharmacology; 2005 Mar; 48(3):343-53. PubMed ID: 15721166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the receptor-state affinity constants of ligands in functional studies using wild type and constitutively active mutant receptors: Implications for estimation of agonist bias.
    Ehlert FJ; Stein RS
    J Pharmacol Toxicol Methods; 2017; 83():94-106. PubMed ID: 27725245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
    Keov P; Sexton PM; Christopoulos A
    Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential.
    Kew JN
    Pharmacol Ther; 2004 Dec; 104(3):233-44. PubMed ID: 15556676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
    Valant C; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of receptor allosterism and its implication for drug discovery.
    Zhang R; Kavana M
    Expert Opin Drug Discov; 2015 Jul; 10(7):763-80. PubMed ID: 25927503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation at the putative GABA(A) ion-channel gate reveals changes in allosteric modulation.
    Thompson SA; Smith MZ; Wingrove PB; Whiting PJ; Wafford KA
    Br J Pharmacol; 1999 Jul; 127(6):1349-58. PubMed ID: 10455284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric targeting of receptor tyrosine kinases.
    De Smet F; Christopoulos A; Carmeliet P
    Nat Biotechnol; 2014 Nov; 32(11):1113-20. PubMed ID: 25380447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.
    Berg KA; Clarke WP
    Int J Neuropsychopharmacol; 2018 Oct; 21(10):962-977. PubMed ID: 30085126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
    Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is pharmacological 'affinity'? Relevance to biased agonism and antagonism.
    Kenakin T
    Trends Pharmacol Sci; 2014 Sep; 35(9):434-41. PubMed ID: 25042457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain.
    Christensen DZ; Mikkelsen JD; Hansen HH; Thomsen MS
    J Neurochem; 2010 Aug; 114(4):1205-16. PubMed ID: 20533993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity.
    Nguyen AT; Vecchio EA; Thomas T; Nguyen TD; Aurelio L; Scammells PJ; White PJ; Sexton PM; Gregory KJ; May LT; Christopoulos A
    Mol Pharmacol; 2016 Dec; 90(6):715-725. PubMed ID: 27683013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.